Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Pliant Therapeutics, Inc.
M.D. Anderson Cancer Center
Novartis
Hangzhou Hanx Biopharmaceuticals, Ltd.
University of Pittsburgh
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Genentech, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
7 Hills Pharma, LLC
Istituto Oncologico Veneto IRCCS
OncoC4, Inc.
Pfizer
Genmab
USWM, LLC (dba US WorldMeds)
Pfizer
National Institutes of Health Clinical Center (CC)
Eastern Cooperative Oncology Group
Aulos Bioscience, Inc.
Ipsen
Memorial Sloan Kettering Cancer Center
Sotio Biotech Inc.
Bristol-Myers Squibb
National Cancer Institute (NCI)
Pfizer
Brigham and Women's Hospital
Hoffmann-La Roche
AstraZeneca
Centre Oscar Lambret
Dana-Farber Cancer Institute
Mayo Clinic
BioNTech SE
Hoffmann-La Roche
Psyence Australia Pty Ltd
M.D. Anderson Cancer Center
Neonc Technologies, Inc.
ViroMissile, Inc.
Erasca, Inc.
Dana-Farber Cancer Institute
Kaiser Permanente
Children's Oncology Group
Pfizer
University of Florida
Arvinas Inc.
Tizona Therapeutics, Inc